Program
tocilizumab
Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1162 open or running | phase 4since Nov 9, 2009 | Mar 25, 2005 | Jul 30, 2027phase 2 · NCT04524871 |
| Bio-Thera Solutions | 30 open or running | phase 3since Jan 22, 2019 | Jul 12, 2018 | none ahead |
| Bristol-Myers Squibb | 22 open or running | phase 3since Jan 9, 2026 | Feb 7, 2025 | Nov 14, 2028phase 3 · NCT07335562 |
| Fresenius Kabi | 20 open or running | phase 3since Aug 11, 2020 | Aug 30, 2017 | none ahead |
| JW Pharmaceutical | 20 open or running | phase 3since Sep 29, 2010 | Sep 29, 2010 | none ahead |
| Beijing VDJBio | 10 open or running | phase 2since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Biogen | 10 open or running | phase 1since Feb 8, 2024 | Feb 8, 2024 | none ahead |
| Celltrion | 10 open or running | phase 3since Feb 2, 2023 | Feb 2, 2023 | none ahead |
| Mycenax Biotech | 10 open or running | phase 1since Apr 11, 2018 | Apr 11, 2018 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer, adagene-inc, tempest-therapeutics, nikang-therapeutics-inc and immune-onc-therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 30, 2012.
- Apr 19, 2019Phase 1 study in Giant Cell ArteritisHoffmann-La Roche · NCT03923738 · 24 enrolled · Switzerland
- Mar 23, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04320615 · 452 enrolled · United States, Canada, Denmark and more
- Apr 21, 2020Phase 2 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04363736 · 97 enrolled · United States
- Apr 29, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04372186 · 377 enrolled · United States, Brazil, Kenya and more
- May 28, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04409262 · 649 enrolled · United States, Brazil, Russian Federation and more
- Aug 11, 2020Phase 3 study in Arthritis, RheumatoidFresenius Kabi · NCT04512001 · 604 enrolled · Bulgaria, Czechia, Georgia and more
- Aug 21, 2020Phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871 · 518 enrolled · United States, China, France and more
- Dec 16, 2021Phase 1 study in COVID-19Hoffmann-La Roche · NCT05164133 · 2 enrolled · United States, Brazil, Croatia and more
- Feb 2, 2023Celltrion's first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT05725434 · 30 enrolled
- Jul 11, 2023Beijing VDJBio's first study: phase 2 study in Arthritis, RheumatoidNew to Beijing VDJBioBeijing VDJBio · NCT05957107 · 181 enrolled · China
- Jul 20, 2023Phase 1 study in Healthy MenBio-Thera Solutions · NCT05968508 · 300 enrolled · China
- Feb 8, 2024Biogen's first study: phase 1 study in Healthy VolunteerNew to BiogenBiogen · NCT06262477 · 300 enrolled · United States, United Kingdom
- Feb 7, 2025Bristol-Myers Squibb's first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
- Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedBristol-Myers Squibb · NCT07335562 · 92 planned · United States, Belgium, Canada and more
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871
- Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicBristol-Myers Squibb · NCT07335562
- Mar 15, 2029Primary completion: phase 1 study in Autoimmune DiseasesBristol-Myers Squibb · NCT07115745
- Sep 30, 2030Primary completion: phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT03424005
TargetBeta
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on IL6R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sarilumabrule | Sanofi | phase 4 | 27 |
Studies
The newest 60 of 129 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more | 3 | Not yet recruiting | Bristol-Myers Squibb | Nov 14, 2028 | 92 |
| NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more | 1 | Recruiting | Bristol-Myers Squibb | Mar 15, 2029 | 125 |
| NCT06262477Healthy Volunteer · United States, United Kingdom | 1 | Completed | Biogen | Sep 25, 2024 | 300 |
| NCT05968508Healthy Men · China | 1 | Completed | Bio-Thera Solutions | Oct 8, 2024 | 300 |
| NCT05957107Arthritis, Rheumatoid · China | 2 | Completed | Beijing VDJBio | Jun 2, 2023 | 181 |
| NCT05725434Arthritis, Rheumatoid | 3 | UNKNOWN | Celltrion | Apr 1, 2023 | 30 |
| NCT05164133COVID-19 · United States, Brazil, Croatia and more | 1 | Completed | Hoffmann-La Roche | Mar 27, 2024 | 2 |
| NCT04524871Advanced Liver Cancers · United States, China, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 518 |
| NCT04512001Arthritis, Rheumatoid · Bulgaria, Czechia, Georgia and more | 3 | Completed | Fresenius Kabi | Aug 31, 2021 | 604 |
| NCT04409262COVID-19 Pneumonia · United States, Brazil, Russian Federation and more | 3 | Completed | Hoffmann-La Roche | Feb 1, 2021 | 649 |
| NCT04372186COVID-19 Pneumonia · United States, Brazil, Kenya and more | 3 | Completed | Hoffmann-La Roche | Aug 18, 2020 | 377 |
| NCT04363736COVID-19 Pneumonia · United States | 2 | Completed | Hoffmann-La Roche | Aug 12, 2020 | 97 |
| NCT04320615COVID-19 Pneumonia · United States, Canada, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jun 24, 2020 | 452 |
| NCT03923738Giant Cell Arteritis · Switzerland | 1 | Completed | Hoffmann-La Roche | Nov 12, 2020 | 24 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Hoffmann-La Roche | Oct 8, 2025 | 272 |
| NCT03830203Arthritis, Rheumatoid · China | 3 | Completed | Bio-Thera Solutions | Jan 5, 2021 | 621 |
| NCT03606876Arthritis, Rheumatoid · China | 1 | Completed | Bio-Thera Solutions | Jul 17, 2019 | 138 |
| NCT03522012Pharmacokinetics · Australia | 1 | Completed | Mycenax Biotech | Sep 26, 2018 | 190 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Hoffmann-La Roche | Sep 30, 2030 | 1,132 |
| NCT03301883Arthritis, Juvenile · China | 4 | Completed | Hoffmann-La Roche | Sep 4, 2021 | 62 |
| NCT03282851Healthy · New Zealand | 1 | Completed | Fresenius Kabi | Oct 1, 2019 | 696 |
| NCT03202368Giant Cell Arteritis · France | 3 | Completed | Hoffmann-La Roche | Aug 21, 2019 | 3 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT03155347Arthritis, Rheumatoid · China | 3 | Completed | Hoffmann-La Roche | Aug 8, 2022 | 340 |
| NCT02682823Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Jul 29, 2016 | 91 |
| NCT02678988Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2016 | 189 |
| NCT02573012Arthritis, Rheumatoid · France, Germany, Italy and more | 4 | Completed | Hoffmann-La Roche | Feb 9, 2018 | 314 |
| NCT02453256Scleroderma, Systemic · United States, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jan 15, 2018 | 212 |
| NCT02336048Leukemia, Lymphocytic, Chronic, B-Cell · Israel, Italy, Latvia and more | 1 | Terminated | Hoffmann-La Roche | Sep 21, 2018 | 38 |
| NCT02165345Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | Nov 24, 2021 | 82 |
| NCT02046616Arthritis, Rheumatoid · Denmark, Finland, Norway and more | 3 | Completed | Hoffmann-La Roche | Sep 13, 2016 | 133 |
| NCT02046603Arthritis, Rheumatoid · United Kingdom | 3 | Completed | Hoffmann-La Roche | Aug 4, 2016 | 162 |
| NCT02031471Arthritis, Rheumatoid · Belgium, Luxembourg | 3 | Completed | Hoffmann-La Roche | Sep 2015 | 57 |
| NCT02011334Arthritis, Rheumatoid · Argentina, Brazil, Colombia and more | 3 | Completed | Hoffmann-La Roche | Oct 2016 | 285 |
| NCT02010216Arthritis, Rheumatoid · Kazakhstan | 4 | Completed | Hoffmann-La Roche | Jul 2010 | 23 |
| NCT02001987Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Dec 2015 | 139 |
| NCT01991990Healthy Volunteer · United Kingdom | 4 | Completed | Hoffmann-La Roche | Dec 2014 | 18 |
| NCT01987479Arthritis, Rheumatoid · Netherlands | 3 | Completed | Hoffmann-La Roche | May 26, 2016 | 150 |
| NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 401 |
| NCT01988012Arthritis, Rheumatoid · Israel | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 100 |
| NCT01951170Arthritis, Rheumatoid · Australia | 3 | Completed | Hoffmann-La Roche | Aug 2015 | 52 |
| NCT01941940Arthritis, Rheumatoid · Italy | 3 | Completed | Hoffmann-La Roche | Sep 9, 2015 | 227 |
| NCT01941095Arthritis, Rheumatoid · Greece | 3 | Completed | Hoffmann-La Roche | Jul 10, 2016 | 100 |
| NCT01904292Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | Jun 13, 2017 | 52 |
| NCT01904279Arthritis, Juvenile · United States, Argentina, Australia and more | 1 | Completed | Hoffmann-La Roche | May 2016 | 52 |
| NCT01878318Arthritis, Rheumatoid | 4 | Withdrawn | Hoffmann-La Roche | Jun 2015 | 0 |
| NCT01791153Giant Cell Arteritis · United States, Belgium, Canada and more | 3 | Completed | Hoffmann-La Roche | Apr 11, 2016 | 251 |
| NCT01772316Arthritis, Rheumatoid · Spain | 3 | Completed | Hoffmann-La Roche | May 2015 | 47 |
| NCT01734382Arthritis, Juvenile · United States, Argentina, Canada and more | 4 | Completed | Hoffmann-La Roche | Oct 9, 2019 | 35 |
| NCT01734993Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Sep 2015 | 11 |
| NCT01730456Arthritis, Rheumatoid · North Macedonia | 3 | Completed | Hoffmann-La Roche | May 2015 | 13 |
| NCT01727986Arthritis, Juvenile · Brazil | 3 | Completed | Hoffmann-La Roche | Nov 2015 | 11 |
| NCT01715831Arthritis, Rheumatoid · Brazil | 4 | Completed | Hoffmann-La Roche | Jun 6, 2016 | 26 |
| NCT01673919Arthritis, Juvenile · France | 3 | Completed | Hoffmann-La Roche | Jan 2014 | 7 |
| NCT01668966Arthritis, Rheumatoid · Brazil | 3 | Completed | Hoffmann-La Roche | May 11, 2016 | 23 |
| NCT01667471Arthritis, Juvenile · Germany | 3 | Completed | Hoffmann-La Roche | Aug 2013 | 6 |
| NCT01665430Arthritis, Rheumatoid · Poland | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 38 |
| NCT01664598Arthritis, Rheumatoid · Russian Federation | 3 | Completed | Hoffmann-La Roche | Jun 2015 | 49 |
| NCT01662063Arthritis, Rheumatoid · United States, Puerto Rico | 3 | Completed | Hoffmann-La Roche | Apr 2014 | 218 |
| NCT01655381Arthritis, Rheumatoid · France | 3 | Completed | Hoffmann-La Roche | Jul 2015 | 15 |
How it is read
Names in the registry
- “Tocilizumab”, 54 entries
- “tocilizumab [RoActemra/Actemra]”, 47 entries
- “MRA(Tocilizumab)”, 11 entries
- “tocilizumab”, 6 entries
- “MSB11456”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 87 studies
- Arthritis, Juvenile, 16 studies
- COVID-19, 5 studies
- Scleroderma, Systemic, 3 studies
- Giant Cell Arteritis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.